Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (81-90 of 325) with videos related to

Pageof 33
Sort By:
Cancer Chemotherapy and Pharmacology|July 6, 2004
A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapySherene Loi, Danny Rischin, Michael Michael, et al.
Expert Opinion on Biological Therapy|May 27, 2021
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeuticsKamal S Saini, Kevin Punie, Chris Twelves, et al.
Breast (Edinburgh, Scotland)|May 21, 2022
Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trialsWanyuan Cui, Kelly-Anne Phillips, Prudence A Francis, et al.
Frontiers in Immunology|February 16, 2018
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy ResponsesAmanda J Oliver, Peter K H Lau, Ashleigh S Unsworth, et al.
BMC Medical Genomics|June 26, 2009
Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancerSherene Loi, Christos Sotiriou, Benjamin Haibe-Kains, et al.
Clinical and Translational Science|May 3, 2024
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancerSenthil Lingaratnam, Mahek Shah, Joseph Nicolazzo, et al.
Plos One|January 10, 2025
Preliminary characterisation of the spatial immune and vascular environment in triple negative basal breast carcinomas using multiplex fluorescent immunohistochemistryElena A Takano, Metta K Jana, Luis E Lara Gonzalez, et al.
American Journal of Cancer Research|January 11, 2023
Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholdersWanyuan Cui, Kelly-Anne Phillips, Richard A Anderson, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapyIvana Bozovic-Spasojevic, Lieveke Ameye, Marianne Paesmans, et al.
Breast (Edinburgh, Scotland)|October 1, 2025
Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitorsJulia Dixon-Douglas, Lauren C Brown, Kate Moodie, et al.
Pageof 33

Showing results (81-90 of 325) with videos related to

Sort By:
Pageof 33
Cancer Chemotherapy and Pharmacology|July 6, 2004
A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapySherene Loi, Danny Rischin, Michael Michael, et al.
Expert Opinion on Biological Therapy|May 27, 2021
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeuticsKamal S Saini, Kevin Punie, Chris Twelves, et al.
Breast (Edinburgh, Scotland)|May 21, 2022
Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trialsWanyuan Cui, Kelly-Anne Phillips, Prudence A Francis, et al.
Frontiers in Immunology|February 16, 2018
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy ResponsesAmanda J Oliver, Peter K H Lau, Ashleigh S Unsworth, et al.
BMC Medical Genomics|June 26, 2009
Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancerSherene Loi, Christos Sotiriou, Benjamin Haibe-Kains, et al.
Clinical and Translational Science|May 3, 2024
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancerSenthil Lingaratnam, Mahek Shah, Joseph Nicolazzo, et al.
Plos One|January 10, 2025
Preliminary characterisation of the spatial immune and vascular environment in triple negative basal breast carcinomas using multiplex fluorescent immunohistochemistryElena A Takano, Metta K Jana, Luis E Lara Gonzalez, et al.
American Journal of Cancer Research|January 11, 2023
Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholdersWanyuan Cui, Kelly-Anne Phillips, Richard A Anderson, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapyIvana Bozovic-Spasojevic, Lieveke Ameye, Marianne Paesmans, et al.
Breast (Edinburgh, Scotland)|October 1, 2025
Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitorsJulia Dixon-Douglas, Lauren C Brown, Kate Moodie, et al.
Pageof 33